For example, when using STING agonists for tumor immunotherapy, the treatment window and toxic side effects must be considered to avoid excessive activation of the STING pathway, which may cause severe inflammation, such as abnormally elevated cytokine levels (Gangadhar and Vonderheide, 2014; Cui et al., 2019). Here, STING1 is linked to neoplasm.